Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study

被引：20

作者：

Garon, E. B. ^{[1
]}

Johnson, M. L. ^{[2
]}

Lisberg, A. E. ^{[3
]}

Spira, A. ^{[4
]}

Yamamoto, N. ^{[5
]}

Heist, R. S. ^{[6
]}

Sands, J. M. ^{[7
]}

Yoh, K. ^{[8
]}

Meric-Bernstam, F. ^{[9
]}

Kitazono, S. ^{[10
]}

Greenberg, J. ^{[11
]}

Kobayashi, F. ^{[12
]}

Kawasaki, Y. ^{[12
]}

Jukofsky, L. ^{[11
]}

Nakamura, K. ^{[11
]}

Shimizu, T. ^{[5
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA

[2] Sarah Cannon Res Inst, Tennessee Oncol, PLLC, OneOncol, Nashville, TN USA

[3] UCLA, Jonsson Comprehens Canc Ctr, Santa Monica, CA USA

[4] Virginia Canc Specialists, Fairfax, VA USA

[5] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Natl Canc Ctr Hosp East, Chiba, Japan

[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[10] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan

[11] Daiichi Sankyo, Basking Ridge, NJ USA

[12] Daiichi Sankyo Co Ltd, Tokyo, Japan

来源：

关键词：

D O I：

10.1016/j.annonc.2021.08.2128

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA49

引用

页码：S1326 / S1327

页数：2